Active Biotech AB - Interim Report January - June 2018
August 09 2018 - 2:30AM
Second quarter in
brief
Events after the end of the
period
-
The company announced that the Phase II
LEGATO-HD trial evaluating efficacy and safety of laquinimod in
Huntington's disease (HD) did not meet its primary endpoint to slow
the progression of the disease. However, the secondary endpoint,
reduction of brain atrophy, was met. Laquinimod showed excellent
safety in the study
-
The company is initiating a scientific
collaboration with the Wistar Institute in Philadelphia, PA, around
tasquinimod to support future clinical development in multiple
myeloma
Financial summary
| SEK M |
Apr-Jun |
Jan-Jun |
Full
year |
| |
2018 |
2017 |
2018 |
2017 |
2017 |
|
|
|
|
|
|
|
| Net
sales |
5.7 |
5.1 |
10.5 |
9.8 |
20.2 |
| Operating
loss |
-7.3 |
-23.1 |
-15.9 |
-37.7 |
-102.5 |
| Loss
after tax |
-9.1 |
-24.4 |
-19.3 |
-40.2 |
-108.8 |
| Earnings
per share (SEK) |
-0.07 |
-0.20 |
-0.15 |
-0.33 |
-0.89 |
| Cash and
cash equivalents (at close of period) |
|
|
45.6 |
47.7 |
25.2 |
For further
information, please contact:
Helén Tuvesson,
CEO
Tel: +46 (0)46 19 21 56
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
|
The report is also available at
www.activebiotech.com.
Active Biotech AB - Interim Report
January - June 2018
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024
